Article Text
Statistics from Altmetric.com
Since the discovery of its broad antiviral activity back 40 years ago1 and as new therapeutic indications are foreseen against emerging viruses,2 ribavirin (RBV), a synthetic triazole analogue of guanosine, has not yet revealed all the secrets of its mechanism of action. Despite this lack of knowledge, RBV has been a critical component of the standard of care ‘dual’ therapy, that is, α-interferon (IFNα) and then pegylated-IFNα (PEG-IFNα) plus RBV, for the treatment of tens of thousands Hepatitis C Virus (HCV)-infected patients worldwide for almost 20 years.3
Several, quite diverse, modes of action have been proposed including: (1) a direct inhibitory effect on viral RNA-dependant RNA-polymerases; (2) lethal mutagenesis of viral nucleic acids; (3) depletion of the cell guanosine triphosphate pool by inhibiting the enzymatic activity of the inosine monophosphate dehydrogenase; (4) modulation of the Th1/Th2 T lymphocyte balance; (5) impairment of the translation via eIF4E inhibition. None of the proposed mechanisms of action convincingly explains RBV-mediated potentiation of IFN-based therapy in HCV-infected patients and, although they are not mutually exclusive, they are all still a matter of controversy (see ref 4 for review). Whereas RBV used in monotherapy has shown little or no effect on HCV viremia5 or HCV genetic heterogeneity,6 it is worth noting that about 50% …
Footnotes
-
BT, ML and DD contributed equally.
-
Contributors All authors contributed equally to the commentary.
-
Funding This research received a specific grant from ANRS, grant number CSS4-AO2-2012 for Basic research support.
-
Competing interests None.
-
Provenance and peer review Commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.